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relationship. This dose effect was already detected in the 2005 
meta-analysis of the Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG) [3] (table  2). Since then, these consolidated 
findings have been consistently taken into account for modern ra-
diotherapy treatment planning [5]. The analysis recently published 
in the New England Journal of Medicine is merely an update of the 
above-cited data and confirms the facts known for years [6].
Cardiotoxicity of Radiotherapy
Pathophysiology and Epidemiology
Cardiotoxicity after radiation therapy is not new and was al-
ready described in detail in the 1970s; clinical research at that time 
focused on young patients with mantle irradiation for Hodgkin’s 
disease. This treatment technique delivered high radiation doses 
to large proportions of the heart. Generally, pericarditis was ob-
served as acute and late toxicity at that time, as well as congestive 
heart failure, ischemic coronary artery disease, arrhythmia, or 
myocardial infarction [7–9]. The leading cause of non-cancer 
mortality among long-term survivors after radiotherapy for Hodg-
kin’s lymphoma was cardiovascular death [10]. It should be noted 
that radiation doses applied to the whole heart have been much 
higher than in the treatment of breast cancer, even in those times 
[11–13]. In Scandinavian breast cancer studies, mainly an in-
creased incidence of ischemic events and unclear cardiac deaths 
was observed [2, 6].
The exact cause of cardiotoxicity after radiotherapy for breast 
cancer is not clear [14]. Based on the clinical data and animal ex-
periments, various causes of radiogenic cardiac toxicity are dis-
cussed. Experimental evidence suggests indirect harmful effects of 
microvascular and macrovascular damage on the myocytes. It has 
been postulated that radiotherapy leads to an acute inflammation 
within the heart blood capillaries and to continuous inflammatory 
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Summary
Radiotherapy is an important component in the multidis-
ciplinary treatment of breast cancer. In recent years, the 
cardiac risks of radiation have been discussed several 
times. This problem has long been known and resolved 
from the radiotherapeutic point of view. The current data 
is briefly described here.
Introduction
It is well known since the first meta-analysis by Cuzick and col-
leagues [1] from the 1980s (incidentally one of the first meta-analy-
sis in medicine at all) that postoperative radiation therapy in breast 
cancer may have adverse effects in long-term survivors. Even then, 
an increased mortality was observed in long-term survivors.
In studies that were started after 1982 [2], these adverse effects 
of radiotherapy have not been observed anymore (table  1). The 
positive effects of radiotherapy therefore came more into play. 
With increasing follow-up, the weight of these recent studies in the 
meta-analyses has grown. This is surely one of the reasons why the 
survival benefit of radiotherapy has become increasingly apparent 
[3, 4]. On the basis of Scandinavian studies and cancer registries, a 
higher rate of cardiac deaths could be identified as the cause for 
increased long-term mortality. This was significant only in patients 
with left-sided breast cancer. Therefore, the radiation exposure of 
the heart was suspected as the cause. Detailed studies primarily 
from Scandinavia were able to demonstrate a clear dose-response 
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processes, resulting in endothelial cell proliferation and formation 
of fibrin thrombi with obstruction of the myocardial capillary 
lumen. Further on, this could lead to ischemia and myocardial cell 
death. Cardiac tissue is replaced by fibrotic tissue, as the myocytes 
have no ability to divide [15]. Subsidiary, radiation also induces an 
inflammatory process in the major arteries of the heart, leading to 
accelerated atherosclerosis. Endothelial cell damage and transmi-
gration of monocytes into the intima lead to the ingestion of lipo-
proteins and the formation of fatty streaks [15]. Therefore, it is 
quite comprehensible that epidemiologic studies detected baseline 
cardiac risk factors as independent risk factor for cardiovascular 
disease after radiotherapy. Those risk factors are age, hypertension, 
diabetes mellitus, total cholesterol, family history of early myocar-
dial infarction, and smoking [15]. In animal experiments, changes 
in the density of beta-receptors are observed at low doses of radia-
tion to the heart. It has been suggested that the increased stimula-
tion of the sympathetic nerve serves to compensate subclinical 
myocardial injury [16]. Perhaps, a combination of all factors de-
scribed above plays a role. Several studies deal with the effect of 
dose on specific cardiac structures in patients undergoing radio-
therapy. Lind et al. [17] evaluated post-radiation regional myocar-
dial heart perfusion changes with single-photon emission tomogra-
phy (SPECT) in 69 patients. They correlated left anterior descend-
ing artery (LAD) distribution SPECT changes with percent irradi-
ated left ventricle (LV) volume and risk factors for coronary artery 
disease. Radiotherapy for left-sided breast cancer was associated 
with short-term SPECT defects in vascular distribution, corre-
sponding to the radiation portals 6 months after radiotherapy. 
They did not find increases in SPECT defects in heart regions out-
side the tangential photon beams. Factors related to the extent of 
perfusion defects were the percent irradiated LV, hormonal treat-
ment, and pre-radiotherapy hypercholesterolemia. None of the pa-
tients experienced clinically significant short-term cardiac events 
like myocardial infarction, but it clearly shows the impact of radio-
therapy on microvascularization in the myocardium. There is cur-
rently no defined threshold dose for the LAD and the definition of 
the LAD as organ at risk is difficult in its reproducibility [18]. Peri-
cardial effusion (PE) in the treatment of breast cancer is a very rare 
effect. Wei et al. [19] reported about PE in patients treated for es-
ophageal cancer. The greatest risk was shown for patients with an 
irradiated heart volume of more than 46% with 30 Gy, resulting in 
73% PE. Those doses are by far not achieved in radiotherapy for 
breast cancer, so that the pericardium as organ at risk does not play 
a definite role in breast cancer radiotherapy. The same applies to 
the aortic bulb and the valvular plane. The incidence of valvular 
disease is only related to mediastinal radiation doses > 30 Gy and 
younger age at irradiation, which was shown for survivors of 
Hodgkin’s disease. After 20 years of follow-up, Machann et al. [20] 
performed cardiac magnetic resonance imaging in 36 patients and 
revealed a hemodynamically relevant valvular dysfunction in 13 




Increase in risk for cardiac death (hazard ratio) in follow-up
Up to 10 years 10–14 years 15–19 years  20 years
1973–1982 1.19 1.35 1.64 1.90
1983–1992 0.99 1.02 1.11 1.21
1993–2002 0.97 0.99 no data
2003–2008 1.00 no data no data no data
Irradiated patients had a higher rate of cardiac deaths compared to the control group without irradiation. 
When listing the studies in chronological order, this was only significant in studies that recruited until 
1982 (significant risks are highlighted in the table in italics). In studies with recruitment from 1983 to 
1992, a very small, not more significant risk resulted after more than 15 years. In subsequent work, in-
creased cardiac mortality was no longer observed (modified from [2]).
Table 1. Increased cardiac mortality only in old 
studies
Heart dose,  
range (mean)
Total number  
of patients
Cardiac events in  
irradiated patients
Cardiac events in non- 
irradiated patients
Hazard ratio  
for annual risk
0–5 Gy (3 Gy) 9,982 2.9% 2.4% 1.08 (n.s.)
5–15 Gy (9 Gy) 7,850 5.4% 3.8% 1.32
> 15 Gy (17 Gy) 2,265 11.0% 6.4% 1.63
Irradiated patients had a higher rate of cardiac deaths. In the low-dose group, this effect was not significant. 
In the group with higher radiation doses, cardiac events even increased in the control group without ir-
radiation. This can be explained mainly by the fact that high doses of radiation were used in the earliest 
studies with long follow-up and thus higher cardiac risk became apparent in non- irradiated patients in 
the control group. As a consequence of the data, one should have an average heart dose of less than 3–5 
Gy in modern technology. Under these conditions, there is no significant cardiac risk [3].
n.s. = Not significant.
Table 2. Data of the EBCTCG, evaluation 2005
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Discussion
The recently published analysis of Darby et al. [6] confirms 
well-known data on cardiac risks in ancient studies and has identi-
fied a dose-response relationship, but it gives no conclusive answer 
to the most important question of how best to protect the heart 
against radiation toxicity. The cardiac radiation doses in the meta-
analysis are rough estimates of each individual patient because 
3-dimensional treatment planning with calculation of cardiac 
doses (which is the contemporary standard) was not yet possible 
[21]. Furthermore, only mean heart doses were presented in 
the analyses. The authors of the New England Journal of 
Medicine article concluded that all exposure of the heart to radia-
tion is associated with an increased risk. From the radiotherapeutic 
point of view, this conclusion is unsustainable after careful analysis 
of the presented data. It is most likely that there is a threshold dose, 
and probably a volume effect. Unfortunately, neither a critical vol-
ume nor a critical threshold dose can be exactly determined based 
on these historical studies. In studies with modern technology (as 
of 1990), no increased rate of cardiac risks was observed [2]. In re-
cent prospective studies, in which the heart dose was calculated as 
part of the treatment planning, the mean heart doses are well below 
the dose of 3 Gy, which is the threshold dose for a significant car-
diac effect recently reported by Darby et al. [6]. As evidence for this 
low cardiac stress, we can refer to our recent multicenter ARO-
2010-01 study. An innovative fractionation schedule (hypofrac-
tionation with integrated boost) was tested, and doses to organs at 
risk were routinely determined and documented during treatment 
planning. The mean heart dose was only 1.48 + 0.9 Gy (n = 151) 
[22]. Analyzing the more common normofractionated standard 
adjuvant tangential radiotherapy in breast cancer, another one of 
our own recent treatment studies also proved low cardiac toxicity. 
We found a mean heart dose of 3.9 Gy (range 1.7–6.1 Gy, standard 
deviation (SD) 2.2 Gy), using a widespread modern computed to-
mography (CT)-based 3-dimensional radiotherapy planning [23]. 
The irradiation dose to the heart is low even when the planning 
target volume (PTV) is enlarged in comparison to routinely stand-
ard tangential radiotherapy, as demonstrated by the recently com-
pleted European Organisation for Research and Treatment of Can-
cer (EORTC) study 22922. The study showed an advantage of ad-
ditional irradiation of the parasternal lymph nodes. No increased 
cardiac mortality was seen although, from experience, the highest 
cardiac doses result from the irradiation of the parasternal lymph 
nodes [24]. Even in the combination of radiation therapy and 
chemotherapy with cardiotoxic drugs (e.g. anthracyclines, trastu-
zumab), no increased risk due to radiotherapy was observed [25–
27]. The cardiac risk of radiotherapy in breast cancer is certainly 
less than the risks of several drug therapies. However, up to now, it 
still remains unclear if late effects after combination of both thera-
pies can become manifest in old age with decreasing compensation 
ability of the heart. Finally, this is not a specific radiotherapeutic 
problem [27].
New Techniques for Cardiac Protection
At present, the deep inspiration breath hold technique (DIBH) 
is increasingly used more or less routinely [28–30]. In deep inspira-
tion, the heart sinks down and the distance to the chest wall in-
creases. First dosimetric studies on individual patients showed a 
significant reduction in heart and lung dose (figs. 1 and 2). It has to 
be clarified whether the unique dosimetric advantage is clinically 
relevant or not, so that the use of this method is currently not man-
datory. Irradiation in prone position is another promising treat-
Fig. 1. Dose distribution in radiotherapy of the left breast during free breath-
ing (left) and DIBH technique (right). The 3-dimensional dose distributions on 
corresponding CT sections (same height in the chest) show that the contours of 
the heart are different and the distance between the heart and the radiation field 
is greater for inspiration. This leads to a lower radiation dose to the heart, evi-
dent in the dose-volume histogram (top center). The median heart dose is al-
most identical, but the maximum dose is significantly reduced by the DIBH 
technique.
Fig. 2. Irradiation with deep inspiration and respiratory arrest. The patient 
wears a belt, by which the breathing is detected. In the control room, the techni-
cian can follow the respiratory excursions on the monitor. Irradiation is per-
formed in a defined respiratory position (after command: ‘Please inhale deeply 
and hold the breath’) and may be interrupted. Depending on the duration of 
irradiation (usually 20–30 s per irradiation field) 1 or 2 respiratory cycles per 
treatment field are required.
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ment option. Several publications are in favor of replacing the su-
pine standard treatment by the prone position for whole-breast ir-
radiation, especially in patients with large breasts [31–33]. Re-
cently, Mulliez et al. [31] reported a phase III randomized trial in 
this context, in which skin desquamation, dermatitis and edema 
were significantly reduced. Moreover, also the dose to the ipsilat-
eral lung and the left anterior descending coronary artery were sig-
nificantly reduced. Comparing the prone and supine treatment 
positions in 400 patients, Formenteri et al. [33] evaluated the in-
field volumes of the heart receiving the full dose as a surrogate for 
normal-tissue exposure. They described a considerable anatomical 
variability of the volume range, but were also able to show a signifi-
cantly lower mean dose to the heart in the prone position. Another 
way to reduce heart toxicity in radiotherapy of breast cancer is the 
use of the evolving techniques in accelerated partial breast irradia-
tion (APBI), which exclusively targets only the lumpectomy site 
plus some margin. The rationale for APBI is based on the fact that 
75–85% of the local recurrences after breast cancer surgery oc-
curred at or near the original lumpectomy site [34]. Current tech-
niques in the delivery of APBI are intraoperative radiotherapy 
(IORT), multi-interstitial brachytherapy, intracavitary brachyther-
apy, and also external beam radiotherapy. The available data on 
APBI suggests acceptable local control and survival in selected pa-
tients with low-risk breast cancer. However, APBI is not applicable 
in patients with high-risk features as evidence from modern trials 
with long-term follow-up is still missing in this context [35]. There 
are also a rising number of patients undergoing oncoplastic sur-
gery, for which the role of APBI is also not yet defined. Further on, 
the techniques of APBI are not widely available and only delivered 
in specialized radiooncology departments. The German S3 guide-
lines from 2012 [36] state that APBI as sole intra- or postoperative 
radiation treatment does not represent the standard of care at that 
time. Outside of clinical trials, APBI should only be delivered to 
patients for whom whole-breast radiotherapy is not applicable.
Conclusion for Daily Practice
A significant cardiotoxicity in modern adjuvant radiotherapy 
for breast cancer has not been observed with the currently used 
modern radiation techniques, neither in simple nor in complex 
planning target volumes. This relates also to the combination of 
irradiation with chemotherapy and immunotherapy. Radiotherapy 
is now safer than in the past, but a longer follow-up is needed in 
order to verify the exact late effects.
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